发明公开
- 专利标题： PHARMACEUTICAL COMPOSITIONS OF MELANOCORTIN RECEPTOR LIGANDS
- 专利标题（中）： 黑色素受体配体的药物组合物
-
申请号： EP10830850.3申请日： 2010-11-15
-
公开(公告)号： EP2501225A1公开(公告)日： 2012-09-26
- 发明人: DONG, Zheng Xin , ZHANG, Jundong
- 申请人： Ipsen Pharma S.a.S.
- 申请人地址： 65 quai Georges Gorse 92100 Boulogne-Billancourt FR
- 专利权人： Ipsen Pharma S.a.S.
- 当前专利权人： Ipsen Pharma S.a.S.
- 当前专利权人地址： 65 quai Georges Gorse 92100 Boulogne-Billancourt FR
- 代理机构： Harrison Goddard Foote
- 优先权： US281360P 20091116
- 国际公布： WO2011060352 20110519
- 主分类号： A01N25/00
- IPC分类号： A01N25/00
摘要：
The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH
2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.
2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.
公开/授权文献
- EP2501225B1 PHARMACEUTICAL COMPOSITIONS OF MELANOCORTIN RECEPTOR LIGANDS 公开/授权日：2017-11-01
信息查询
